Pharming Group Shares Surge 11.33% at Thursday's Close
Pharming Group shares closed Thursday, January 22, at 1.69 euros, marking a remarkable surge of 11.33% from the previous day. This spike occurred as the Dutch laboratory specializing in rare diseases unveiled a higher-than-expected 2025 revenue of approximately $376 million, surpassing the revised range of $365 to $375 million announced in November, representing about a 27% growth from 2024. This strong performance reflects the continued growth of RUCONEST and the increasing demand for Joenja, mainly driven by patient adoption in the United States. The group will host a virtual investor day on February 3, 2026, to present its financial outlook and update on its clinical portfolio.
Over the past seven days, the share price has increased by 7.51% and has recorded a rise of 45.06% over three months, demonstrating sustained upward momentum. Pharming Group is approaching a significant regulatory deadline. The U.S. FDA is expected to make its decision on extending leniolisib to children aged 4 to 11 with APDS syndrome by January 31, 2026. Currently, there are no approved treatments for children under 12 with this rare primary immunodeficiency. This potential approval would represent a significant market expansion for the drug, which has been authorized since March 2023 for patients aged 12 and older.
Technical Analysis and Market Sensitivity
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical perspective, the share price is now significantly above its key moving averages. The price of 1.69 euros is 15.75% above the 50-day moving average set at 1.46 euros, and exceeds the 200-day moving average of 1.25 euros by 35.20%. This setup indicates a well-established bullish orientation in the medium and long term. The breach of the resistance level at 1.61 euros is an additional positive technical signal, potentially paving the way for new highs. The RSI indicator stands at 58 points, operating in a neutral zone that leaves room for progression before reaching overbought levels around 70. This situation suggests that the bullish movement still has room to continue without immediate signs of fatigue. The one-month volatility is at 12.79%, while a beta of 0.49 indicates that the stock has moderate sensitivity to market movements. Over one year, the performance reaches 89.89%, placing Pharming Group among the most successful companies in the European biopharmaceutical sector.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 117,6 millions de dollars
Quarterly revenue: 117,6 millions de dollars
Revenue growth: 21 %
Guidance from the release
Tightened 2026 total revenue guidance to between US$380 million and US$390 million from prior US$375 million to US$395 million
Risks mentioned
Joenja revenue growth was partly driven by temporary benefit from ordering patterns in other international markets
RUCONEST third quarter revenue includes an early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer, following significant drawdowns earlier in the year
Napazimone (KL1333): enrollment in the pivotal FALCON trial now expected to complete in the first half of 2027 (about 145 of 180 subjects by end-2026), with topline results approximately one year after completion of enrollment
Opportunities identified
RUCONEST stabilization and continued recovery of demand in the US (third quarter revenue of about US$93.8 million, +14% year-on-year and +30% versus the second quarter of 2026)
Joenja strong growth driven by launches in Germany, Japan and continued penetration in the U.K.
Substantial growth potential for Joenja with estimated CVID with immune dysregulation prevalence of 39 patients per million vs 1.5 for APDS
Outlook / guidance
Expected revenue: 385 millions de dollars
Management commentary: Tightened 2026 total revenue guidance to between US$380 million and US$390 million (1% to 4% growth) from prior US$375 million to US$395 million (0% to 5% growth)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
